After years of waiting, courtesy of Allogene investors at last have an allogeneic Car-T dataset comparable with autologous therapies.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
Datopotamab, a project with a very similar mechanism to Trodelvy, shows impressive early data in triple-negative breast cancer.
The first quarter of 2021 saw fewer deals than any in recent memory.
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.